Pharmacokinetics of tilmicosin in beef cattle following intravenous and subcutaneous administration

Authors


Kimberly R. Lombardi, Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA. E-mail:lombardiki@lilly.com

Abstract

Lombardi, K. R., Portillo, T., Hassfurther, R., Hunter, R. P. Pharmacokinetics of tilmicosin in beef cattle following intravenous and subcutaneous administration. J. vet. Pharmacol. Therap. 34, 583–587.

The intravenous pharmacokinetic profile of tilmicosin is yet to be achieved because of the cardiovascular effects of tilmicosin. This study summarizes two pharmacokinetic studies that provided complete pharmacokinetic profile of tilmicosin in cattle. The first study was a pharmacokinetic study of tilmicosin in beef calves dosed by i.v. infusion over 5 h. The second study was a subcutaneous (s.c.) pharmacokinetic study comparing the pharmacokinetic profile of tilmicosin in light (approximately 170 kg) and heavy (approximately 335 kg) beef cattle and comparing the labeled dose range of 10 or 20 mg/kg dose. The data from the two different studies were used to calculate bioavailability values, which support the assumption that tilmicosin is 100% bioavailable in cattle. The results from the second study showed that the weight of an animal when administered tilmicosin does not have a significant effect on exposure, but did demonstrate that doubling the dose of tilmicosin administered doubles the systemic exposure to tilmicosin.

Ancillary